MAP2K1 and melanoma: In this study, we assessed the impact of three generations of mTOR kinase inhibitors, administered both individually and in combination with the MEK1/2 inhibitor AS-703026, on the expression of key adhesion and structural proteins in MEWO melanoma cells.